The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment – Blood Cancer Journal

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and…

Read the full article here

Source: Blood Cancer Journal

Categories: Hem/Oncs, Latest Headlines

Tags: CCC19, COVID19nCancer, covid19vaccine, IDonc, mmsm, NCT04743388

Tweets with this article

Mike Thompson, MD, PhD, FASCO

Neutralizing antibody response post COVID-19 vaccination in Pts w/ myeloma is highly dependent on the type of anti-myeloma Tx [Aug 2, 2021] Terpos et al. @BloodCancerJnl https://t.co/dff3ZgPf5Z #NCT04743388 #COVID19Vaccine #COVID19nCancer #CCC19 #mmsm #IDonc HT @CyclingDoctor https://t.co/W3LtZA91rB

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined…

Mike Thompson, MD, PhD, FASCO April 23, 2024

Real-World Clinical Genomic Analysis of Patients with BRAF Mutated Cancers Identifies BRAF Class II and III as a Population of Unmet Medical Need – Tempus

Background Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are…

Mike Thompson, MD, PhD, FASCO April 23, 2024

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms

TO THE EDITOR:

Mike Thompson, MD, PhD, FASCO April 23, 2024

RAS/RAFlandscape in monoclonal plasma cell conditions.

Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event

Mike Thompson, MD, PhD, FASCO April 23, 2024

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Key Points. Quantification of the primary myeloma cell surface proteome enables unbiased discovery of novel therapeutic targets.Targeting SEMA4A using an a

Mike Thompson, MD, PhD, FASCO April 23, 2024

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma

Amplification of chromosome 1q (chr1q-amp) is an adverse prognostic feature in multiple myeloma (MM). In this Plenary paper, Trasanidis and colleagues perf

Mike Thompson, MD, PhD, FASCO April 23, 2024

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19 | mBio

As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma…

Mike Thompson, MD, PhD, FASCO April 20, 2024

Related Articles